Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback